Edition:
India

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

1.01USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
155,333
52-wk High
$10.00
52-wk Low
$0.80

Summary

Name Age Since Current Position

Timothy Walbert

50 2015 Independent Chairman of the Board

Robert Radie

52 2012 President, Chief Executive Officer, Director

Stanley Musial

55 2015 Chief Financial Officer, Executive Vice President, Secretary

Mark Strobeck

45 2015 Chief Operating Officer, Executive Vice President

Paul Varki

2015 Senior Vice President, General Counsel

E. Blair Clark-Schoeb

Senior Vice President - Communications

Karsten Lindhardt

44 2013 Senior Vice President - Research & Development

Barbara Carlin

41 2016 Chief Accounting Officer

Jeffrey Dayno

59 2014 Chief Medical Officer

Patrick Shea

2016 Chief Commercial Officer

Robert Roche

61 2016 Director

Jean-Francois Formela

61 2015 Independent Director

Nicholas Nicolaides

50 2015 Independent Director

John Osborn

58 2015 Independent Director

Gregory Weaver

61 2014 Independent Director

Biographies

Name Description

Timothy Walbert

Mr. Timothy P. Walbert is Independent Chairman of the Board of the Company. Mr. Walbert has served as a member of the Board since March 2014 and as Chairman of the Board since June 2015. Mr. Walbert has been president and chief executive officer of Horizon Pharma since June 2008 and the chairman of the board of directors since April 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a public biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager, Immunology, where he led the global development and launch of the multi-indication biologic HUMIRA which exceeded $14.0 billion in sales in 2015 and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. Mr. Walbert received his B.A. in business from Muhlenberg College in Allentown, Pennsylvania. Mr. Walbert sits on the boards of directors of XOMA Ltd, a public biotechnology company, Sucampo Pharmaceuticals, Inc., a public biopharmaceutical company, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), World Business Chicago (WBC), the Greater Chicago Arthritis Foundation and the Illinois Innovation Council and serves as the chairman of the Illinois Biotechnology Industry Organization (iBIO). Mr. Walbert is also a member of the Illinois Innovation Council. Mr. Walbert previously served on the board of directors of Raptor Pharmaceuticals Corp., a public biopharmaceutical company, from 2010 to 2014. Mr. Walbert was appointed by Illinois Governor Pat Quinn in 2013 to the Illinois Innovation Council.

Robert Radie

Mr. Robert Radie is President, Chief Executive Officer, Director of Egalet Corp. Mr. Radie is our President and Chief Executive Officer and a member of the Board, positions he has held since March 2012. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2008 to December 2008, Mr. Radie was unemployed. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company, and as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie is currently a member of the board of directors of Paratek Pharmaceuticals (NASDAQ: PRTK), a position he has held since November 2014, and also serves as a director of Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2007. Mr. Radie received his B.S. in Chemistry from Boston College.

Stanley Musial

Mr. Stanley (Stan) J. Musial is Chief Financial Officer, Executive Vice President, Secretary of Egalet Corp. Mr. Musial has served as our Chief Financial Officer since April 2013, as our Secretary since September 2013 and as an Executive Vice President since December 2015. From June 2011 to March 2013, Mr. Musial was self-employed, acting as an independent consultant in the fields of financial management and accounting services. From January 2005 to May 2011, Mr. Musial served as Chief Financial Officer of Prism Pharmaceuticals, Inc., a specialty pharmaceutical and drug development company. Prior to joining Prism Pharmaceuticals, Mr. Musial was Vice President, Finance, and Chief Financial Officer for Strategic Diagnostics, Inc., a publicly-held biotechnology company, from 2002 to 2004. Mr. Musial began his career with KPMG LLP, a professional services company. Mr. Musial received a B.S. in Accounting from the Pennsylvania State University and an M.B.A. from Temple University. He is a Certified Public Accountant in the Commonwealth of Pennsylvania.

Mark Strobeck

Dr. Mark Strobeck Ph.D. is Chief Operating Officer, Executive Vice President of Egalet Corp. Dr. Strobeck is our Executive Vice President and Chief Operating Officer, a position he has held since September 2015 and previously served as our Chief Business Officer from January 2014 to September 2015. Prior to his employment at Egalet, he was our adviser to from June 2012 to December 2013. From January 2012 to December 2013, Dr. Strobeck served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., which was acquired by AstraZeneca in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline, SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the Board of Directors of Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology from the University of Cincinnati, and completed his post-doctoral fellowship at the University of Pennsylvania.

Paul Varki

Mr. Paul C. Varki , J.D., M.P.H, is Senior Vice President, General Counsel of Egalet Corporation. Mr. Varki is our senior vice president and general counsel, a position he has held since November 2015. Prior to Egalet he served as assistant general counsel at GlaxoSmithKline (GSK), providing global legal support for research and development. Before that position he served as senior counsel for GSK’s vaccines business unit within North America, and counsel for marketed products within the U.S. pharmaceuticals business. Mr. Varki practiced food and medical device drug law at Reed Smith and served as regulatory counsel for the Food and Drug Administration (FDA) and the Center for Drug Evaluation and Research (CDER). He earned his law degree from Temple University Law School, earned his master of public health from George Washington University School of Public Health and received his bachelor’s degree from the College of William and Mary.

E. Blair Clark-Schoeb

Ms. E. Blair Clark-Schoeb is a Senior Vice President - Communications of the Company. Ms. Clark-Schoeb, senior vice president, communications, leads our investor relations, public relations, advocacy relations and government affairs work. She has two decades of experience helping healthcare companies develop unique and effective communications programs. Prior to joining Egalet in February 2015, Ms. Clark-Schoeb led her own consulting business, working with pharmaceutical and biotechnology companies such as Sanofi, Syndax, Horizon Pharmaceuticals and Topaz Pharmaceuticals. Prior to that she was senior associate at W2O, director of investor relations at Burns McClellan, director of corporate finance at The Medicines Company and a healthcare investment banker at Donaldson, Lufkin and Jenrette. Ms. Clark-Schoeb received her bachelor’s degree from Harvard University.

Karsten Lindhardt

Dr. Karsten Lindhardt, Ph.D., is a Senior Vice President - Research & Development of Egalet Corp. Dr. Lindhardt has served as our Senior Vice President, Research and Development since December 2013 and previously served as our Vice President, Research and Development from April 2011 to December 2013 and as our Senior Director of Portfolio Management and Alliance Manager from May 2010 to April 2011. From August 2008 to May 2010, Dr. Lindhardt served as the Director of Portfolio Management for our predecessor Egalet A/S, and as a Project Manager from March 2008 to August 2008. Before joining Egalet A/S, Dr. Lindhardt served in management positions for Curalogic A/S, Prosidion Ltd. and OSI Pharmaceuticals, and as a clinical pharmacologist for Ferring Pharmaceuticals and Novo Nordisk A/S. Dr. Lindhardt has earned a Diploma of Business Excellence at Columbia University, Copenhagen Business School. Dr. Lindhardt received a M.Sci. in Pharmaceutics and a Ph.D. in pharmaceutical development and pharmacology, each from the Royal Danish School of Pharmacy.

Barbara Carlin

Ms. Barbara Carlin is Chief Accounting Officer of Egalet Corporation. Ms. Carlin is our chief accounting officer a position she’s held since January 2016. She joined Egalet in January 2014 as vice president, finance and administration. For more than 15 years Ms. Carlin has provided financial and operational leadership to public and privately held companies with a focus on the emerging growth life sciences community. During that time, she worked at several biotechnology and specialty pharmaceutical companies including: Topaz Pharmaceuticals Inc., moksha8 Pharmaceuticals, Inc., Genaera Corporation and Vicuron Pharmaceuticals, Inc. She also served in various roles in finance and accounting at publically held companies in the professional services and publishing space. Ms. Carlin started her career in accounting at Deloitte and Touche LLP. She earned her bachelor’s degree in accounting from St. Joseph’s University and is a certified public accountant in the Commonwealth of Pennsylvania.

Jeffrey Dayno

Dr. Jeffrey M. Dayno, M.D., has been appointed as Chief Medical Officer of the Company effective July 31, 2014. From May 2014 to June 2014 Dr. Dayno served as our consultant. Prior to joining Egalet, Dr. Dayno served as vice president, global medical affairs, at ViroPharma Inc., a pharmaceutical company acquired by Shire Pharmaceuticals Group plc in early 2014, where he was a member of several senior research and development leadership teams and the portfolio management team, from August 2011 to April 2014. Prior to joining ViroPharma, Dr. Dayno held the position of chief medical officer at Labopharm, Inc., a Canadian biotechnology company, from May 2010 to July 2011, where he oversaw all of Labopharm’s research and development activities and gained valuable experience working in the area of abuse-deterrent opioid product development. Before joining Labopharm, Dr. Dayno served as the vice president, medical services, at Cephalon Inc. from December 2005 to April 2010, where he directed Cephalon’s Phase 3B/4 clinical development programs. Dr. Dayno started his career in the pharmaceutical industry at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. Dr. Dayno was a board certified neurologist and completed fellowship training in stroke and cerebrovascular diseases at Henry Ford Hospital, which held the NIH Program Grant for both Stroke and Migraine/Headache Disorders. He spent ten years in academic/clinical medicine, during which time he served as the principal investigator on numerous clinical trials in the areas of stroke and migraine. In May 2014, Dr. Dayno was invited to serve on the Board of Visitors of Temple University School of Medicine, where he continues to be an active board member.

Patrick Shea

Mr. Patrick M. Shea has been appointed as Chief Commercial Officer of the Company. Mr. Shea has over two decades of sales, marketing, market access and commercial operations experience. Most recently Mr. Shea served as CCO at Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company. Prior to Clarus he served as vice president of sales and marketing for the U.S. commercial operations of CSL Behring, where he oversaw strategic efforts for sales, marketing and managed care business. Before that he served as senior vice president of sales and marketing for the U.S. pharmaceutical operations at Astellas Pharmaceuticals, and held senior sales and marketing roles at Lig and Pharmaceuticals and Boehringer Ingelheim. Mr. Shea received his bachelor's degree in Psychology from Alfred University.

Robert Roche

Mr. Robert P. Roche, Jr. serves as Director of the Company. Mr. Roche is the founding member of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. He founded this firm upon his retirement from Cephalon, Inc. in February 2010. Mr. Roche joined Cephalon, Inc. in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations of Cephalon, Inc. in 2005. Before joining Cephalon, Inc., Mr. Roche held various positions at SmithKline Beecham Pharmaceuticals from 1982 to 1994, including as Director and Vice President, Worldwide Strategic Product Development for SmithKline Beecham’s central nervous system and gastrointestinal products. Mr. Roche also serves on the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX), Antares Pharma, Inc. (NASDAQ: ATRS), Paragon Bioservices, Inc. and Bryn Mawr Hospital.

Jean-Francois Formela

Dr. Jean-Francois Formela, M.D., is Independent Director of the Company. Dr. Formela has served as a member of the Board since September 2010 served as chair from March 2012 until June 2015. He is currently a partner at Atlas Venture, an early stage venture capital firm focused on investments in biological and drug discovery technologies, and has served in such capacity since joining Atlas Venture in 1993. He also serves on the board of directors of RaNA Therapeutics, Inc., which he co-founded, and serves on the board of directors of the following privately held companies: Ataxion, Inc., F-star Beta Ltd., Intellia Therapeutics, Inc., Navitor Pharmaceuticals, Inc., Spero Therapeutics, LLC and ZappRx, Inc. Within the last five years, Dr. Formela has also served on the boards of directors of the following public companies: ARCA biopharma, Inc., Horizon Pharma, Inc. and Achillon Pharmaceuticals, Inc. Prior to joining Atlas Venture, Dr. Formela served as a senior director of medical marketing and scientific affairs at Schering-Plough Corporation, a pharmaceutical company which merged with Merck & Co., Inc.. Dr. Formela began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Dr. Formela is a member of the Massachusetts General Hospital Research Advisory Council and a trustee of the Boston Institute of Contemporary Art. He received his M.D. from the Paris University School of Medicine and his M.B.A. from Columbia University.

Nicholas Nicolaides

Dr. Nicholas C. Nicolaides, Ph.D., is an Independent Director of the Company. Dr. Nicolaides has served as a member of the Board since April 2015. Dr. Nicolaides is the President, Chief Executive Officer and co-founder of Morphotek® Inc., a biopharmaceutical company specializing in the development of protein and antibody therapeutics through the use of a proprietary gene evolution technology. He has served as President and CEO of Morphotek since its founding in 2000. Morphotek was acquired by Eisai, Co. Ltd. of Japan in 2007 and continues to operate as an autonomous subsidiary. Morphotek has developed a pipeline of therapeutic antibodies in the areas of cancer, inflammation and infectious disease. Dr. Nicolaides is a trained molecular geneticist and has authored over 50 peer-reviewed scientific papers on the molecular and genetic basis of cancer and respiratory diseases and holds over 50 issued patents. He received a B.S. in Biology from St. Joseph’s University, Philadelphia, PA, a Ph.D. in genetics from Thomas Jefferson University, Philadelphia, PA and a Fellowship in oncology from Johns Hopkins University, Baltimore, MD. While at Johns Hopkins, his research resulted in the discovery of the genetic cause of one of the most common forms of inherited cancer and the development of Morphotek’s platform technology called morphogenics. He has been recognized by R&D Directions’ as one of the Top 20 Most Notable People in Research and Development and received the Ernst & Young’s Entrepreneur of the Year award as well as the Pennsylvania Governor’s Entrepreneur Impact Award for his successful accomplishments in founding and expanding Morphotek’s product pipeline and operations. He currently serves as an ad hoc reviewer for several immunology and cancer research journals; is a member of the American Association for Cancer Research and New York Academy of Sciences; and serves on the Dean’s Advisory Board of St. Joseph’s University’s.

John Osborn

Mr. John E. Osborn is an Independent Director of the Company. Mr. Osborn has served as a member of the Board since April 2015. Mr. Osborn currently serves as a Senior Advisor in the Corporate & Government Regulatory Practice Groups with the law firm Hogan Lovells US LLP, a position he has held since December 2013, and as an Executive-in-Residence/Industry Advisor with the Healthcare and Consumer Group of the global private equity firm Warburg Pincus, a position he has held since August 2013. He also holds a faculty appointment as an affiliate professor of law at the University of Washington, Seattle, a position he has held since April 2012. From June 2012 to March 2013, he was the Senior Vice President of Global Corporate Affairs at Onyx Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and marketing cancer therapeutics. From August 2011 to June 2012, he served in various senior management and advisory positions with Dendreon Corporation, a biotechnology company focused on manufacturing and marketing an innovative oncology immunotherapy, including as Executive Vice President, General Counsel & Secretary. From August 2010 to February 2011, he was the Executive Vice President & General Counsel of US Oncology, Inc., a Fortune 1000 physician management and oncology services company, where he worked prior to and immediately following its acquisition by McKesson Corporation. Mr. Osborn was nominated by President George W. Bush and confirmed by the Senate as a member of the United States Advisory Commission on Public Diplomacy, where he served from 2008 to 2011. He earned a B.A. in economics and history from the University of Iowa, a M.I.P.P. from The Johns Hopkins University, and a J.D. from the University of Virginia, and was a visiting fellow in politics at Princeton University.

Gregory Weaver

Mr. Gregory L. Weaver is Independent Director of Egalet Corp. Mr. Weaver has served as a member of the Board since February 2014. Since November 2015, Mr. Weaver has served as the Chief Financial Officer of Prometic Life Sciences, Inc., a biopharmaceutical company focused on bioseparation, plasma-derived therapeutics and small-molecule drug development, and from January 2015 to October 2015 served as the Executive Vice President and Chief Financial Officer of Oryzon Genomics, S.A. From November 2014 to December 2014, Mr. Weaver worked as a consultant. From August 2013 until October 2014, Mr. Weaver has served as the Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science, Inc., a publicly held cell therapy company. From June 2011 to July 2013, Mr. Weaver served as Senior Vice President and Chief Financial Officer of Celsion Corporation, a publicly held biotechnology company, and was a director and chairman of the audit committee of Celsion’s Board of Directors from 2005 to 2011. From February 2009 to September 2010, Mr. Weaver served as Senior Vice President and Chief Financial Officer of Poniard Pharmaceuticals, a public oncology drug development company. Mr. Weaver currently serves on the board of directors and audit committee, and is the chairman of the compensation committee, of Atossa Genetics, a publicly held diagnostics company, and also served as a director and chairman of the audit committee of SCOLR Pharmaceuticals, a public drug delivery company, from 2007 to 2009. Mr. Weaver is a certified public accountant and received an M.B.A. from Boston College and a B.S. in accounting from Trinity University.